Evidence map›Paper›PMID 37566052›Full record

ArticleCells2023

DCUN1D1 Is an Essential Regulator of Prostate Cancer Proliferation and Tumour Growth That Acts through Neddylation of Cullin 1, 3, 4A and 5 and Deregulation of Wnt/Catenin Pathway.

Akhona Vava, Juliano D Paccez, Yihong Wang, Xuesong Gu, Manoj K Bhasin, Michael Myers, Nelson C Soares, Towia A Libermann, Luiz F Zerbini

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

Akhona VavaCancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town 7925, South Africa.
Juliano D PaccezCancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town 7925, South Africa.ORCID 0000-0002-1086-4588
Yihong WangDepartment of Pathology and Laboratory Medicine, Warren Alpert School of Medicine, Brown University, Providence, RI 02912, USA.
Xuesong GuBIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Manoj K BhasinDepartment of Pediatrics Bioinformatics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Michael MyersProtein Networks Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy.
Nelson C SoaresDepartment of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates.
Towia A LibermannBIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-4006-8179
Luiz F ZerbiniCancer Genomics Group, International Centre for Genetic Engineering and Biotechnology, Cape Town 7925, South Africa.ORCID 0000-0003-0736-9508
Beth Israel Deaconess Medical Center · USInternational Centre for Genetic Engineering and Biotechnology · ZABrown University · USEmory University · USInternational Centre for Genetic Engineering and Biotechnology · ITUniversity of Cape Town · ZAUniversity of Sharjah · AE

Funding

Role of Axl in docetaxel resistance in prostate cancerR21CA187843 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LIBERMANN, TOWIA A. · 2015 to 2016
$372k
NCI NIH HHS R21 CA187843
6 · The paper itself

Abstract

Defective in cullin neddylation 1 domain containing 1 (DCUN1D1) is an E3 ligase for the neddylation, a post-translational process similar to and occurring in parallel to ubiquitin proteasome pathway. Although established as an oncogene in a variety of squamous cell carcinomas, the precise role of DCUN1D1 in prostate cancer (PCa) has not been previously explored thoroughly. Here, we investigated the role of DCUN1D1 in PCa and demonstrated that DCUN1D1 is upregulated in cell lines as well as human tissue samples. Inhibition of DCUN1D1 significantly reduced PCa cell proliferation and migration and remarkably inhibited xenograft formation in mice. Applying both genomics and proteomics approaches, we provide novel information about the DCUN1D1 mechanism of action. We identified CUL3, CUL4B, RBX1, CAND1 and RPS19 proteins as DCUN1D1 binding partners. Our analysis also revealed the dysregulation of genes associated with cellular growth and proliferation, developmental, cell death and cancer pathways and the WNT/β-catenin pathway as potential mechanisms. Inhibition of DCUN1D1 leads to the inactivation of β-catenin through its phosphorylation and degradation which inhibits the downstream action of β-catenin, reducing its interaction with Lef1 in the Lef1/TCF complex that regulates Wnt target gene expression. Together our data point to an essential role of the DCUN1D1 protein in PCa which can be explored for potential targeted therapy.

Indexed as

Cullin ProteinsIntracellular Signaling Peptides and ProteinsProstatic NeoplasmsAnimalsbeta CateninCateninsCell ProliferationHumansMaleMiceProto-Oncogene ProteinsWnt Signaling Pathwaybeta CateninCateninsCUL4B protein, humanCullin 1Cullin ProteinsDCUN1D1 protein, humanIntracellular Signaling Peptides and ProteinsProto-Oncogene ProteinsDCUN1D1E3 ligaseneddylationprostate cancerWnt/β-catenin pathway

Identifiers

PMID37566052
PMCPMC10417424
OpenAlexW4385428752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.